Streamlining Pulmonology Express Scripts Integration for Biologics and Specialty Meds

Effective pulmonology Express Scripts integration is crucial for accelerating access to high-cost biologics and specialty medications, minimizing administrative burden for respiratory care teams.

For revenue cycle directors and prior authorization coordinators in pulmonology, managing pharmacy benefit manager (PBM) prior authorizations presents a unique challenge. Express Scripts, as a major PBM, dictates specific requirements for numerous critical respiratory therapies, impacting patient access and operational efficiency. Klivira provides a robust solution to automate and accelerate these complex workflows.

The Challenge of Express Scripts Prior Authorization in Pulmonology

Pulmonology practices frequently encounter prior authorization requirements from PBMs like Express Scripts for high-cost specialty drugs. These include biologics for severe asthma such as Dupixent, Nucala, Fasenra, and Tezspire, as well as antifibrotics for Idiopathic Pulmonary Fibrosis (IPF) like Esbriet and Ofev. Navigating varying policy criteria, documentation mandates, and step-therapy protocols can significantly delay patient access to essential treatments.

Key Pulmonology PA Triggers for Express Scripts

Asthma biologics (e.g., omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab)
IPF antifibrotics (e.g., pirfenidone, nintedanib)
Select COPD specialty drugs (e.g., ensifentrine, Trelegy, Breztri)
Home oxygen and BiPAP/CPAP equipment
Pulmonary function testing requiring specific authorization

Navigating Express Scripts PBM Requirements for Respiratory Care

As a PBM, Express Scripts (part of Evernorth pharmacy) manages pharmacy benefit prior authorizations, often requiring electronic prior authorization (ePA) submissions. These interactions typically leverage industry standards like NCPDP SCRIPT and X12 278 for communication. Pulmonology teams must meticulously address criteria such as eosinophil counts for IL-5 targeting biologics, documented failure of prior controller therapies, and adherence to specific step-therapy protocols defined by the PBM.

Klivira's Approach to Pulmonology Express Scripts Integration

Klivira's platform is engineered to streamline the prior authorization process for pulmonology practices interacting with PBMs like Express Scripts. Our solution integrates directly with EMR systems, automating data extraction and submission for common pulmonology PA categories. This includes GINA/GOLD/ATS-aware step-therapy logic and automated documentation capture, significantly reducing manual effort and potential for denial.

Critical Documentation for Pulmonology PAs with Express Scripts

Eosinophil counts (peripheral or sputum where applicable) for asthma biologics
Detailed history of prior controller therapy at maximum tolerated dose
Exacerbation history and severity classification for asthma
Clinical notes demonstrating adherence to ATS, GOLD, and GINA guidelines
Evidence of insufficient conservative therapy for conditions like IPF

Optimizing Workflow: EMR Integration and Payer Touchpoints

Klivira integrates seamlessly with your existing EMR, leveraging standards like SMART on FHIR to pull relevant clinical data directly from patient charts. This automation ensures that necessary documentation, from diagnostic codes to medication history, is accurately compiled and submitted through appropriate ePA channels to PBMs such as Express Scripts. Our system also supports efficient re-authorization workflows for chronic pulmonology conditions, minimizing care disruptions.

Frequently asked questions

What types of pulmonology medications typically require Express Scripts prior authorization?

Express Scripts commonly requires prior authorization for high-cost asthma biologics (e.g., Dupixent, Nucala, Fasenra, Tezspire), IPF antifibrotics (e.g., Esbriet, Ofev), and certain COPD specialty drugs. Authorization for home oxygen and BiPAP/CPAP equipment is also frequently mandated by PBMs.

How does Klivira handle step therapy requirements for asthma biologics with Express Scripts?

Klivira incorporates GINA/GOLD/ATS-aware step-therapy logic into its automation workflows. Our platform helps ensure that documentation of prior controller therapy at maximum doses and other step-therapy prerequisites are accurately captured from the EMR and submitted, aligning with Express Scripts' policy requirements to minimize denials.

What documentation is critical for Express Scripts PAs in pulmonology?

Critical documentation includes eosinophil counts, detailed records of prior controller therapy, exacerbation history, and evidence of severity classification for asthma. For IPF, documentation of insufficient conservative therapy is often required. Adherence to clinical guidelines from bodies like ATS, GOLD, and GINA is also frequently assessed.

Can Klivira integrate with our EMR for pulmonology Express Scripts PAs?

Yes, Klivira is designed for deep EMR integration, utilizing standards like SMART on FHIR. This allows for automated extraction of clinical data directly from patient charts, ensuring that all necessary information for pulmonology prior authorizations, including those for Express Scripts, is accurately compiled and submitted without manual data entry.

How does Klivira support re-authorization workflows for chronic pulmonology conditions?

Klivira provides robust support for re-authorization workflows, which are common for chronic pulmonology conditions requiring ongoing biologic or specialty drug therapy. Our system tracks authorization expiry dates and automates the re-submission process, leveraging previously gathered clinical data and updated patient information to ensure continuous coverage.